Evidence map›Paper›PMID 34908832›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.

Koichiro Takahashi, Hiroki Tashiro, Ryo Tajiri, Ayako Takamori, Masaru Uchida, Go Kato, Yuki Kurihara, Hironori Sadamatsu, Takashi Kinoshita, Makoto Yoshida and 5 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Koichiro TakahashiDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.ORCID 0000-0003-0461-5072
Hiroki TashiroDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Ryo TajiriClinical Research Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan.
Ayako TakamoriClinical Research Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan.
Masaru UchidaDivision of Internal Medicine, Japan Community Health Care Organization Saga Central Hospital, Saga, Japan.ORCID 0000-0002-2474-5619
Go KatoDivision of Respiratory Medicine, Saga Prefectural Medical Center Koseikan, Saga, Japan.
Yuki KuriharaDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Hironori SadamatsuDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Takashi KinoshitaDivision of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Makoto YoshidaDivision of Respiratory Medicine, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.ORCID 0000-0001-6367-3470
Atsushi KawaguchiClinical Research Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Naoko Sueoka-AraganeDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Tomotaka KawayamaDivision of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID 0000-0002-9537-4229
Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group
Saga University · JPKurume University · JPFukuoka Hospital · JPSaga-Ken Medical Centre Koseikan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProlonged sedentary behavior is associated with worse prognosis in patients with chronic obstructive pulmonary disease (COPD). Our previous study found that first-line dual therapy with tiotropium/olodaterol significantly reduces sedentary time compared to tiotropium monotherapy in Japanese patients with treatment-naïve COPD, although the characteristics of responders to dual-therapy versus monotherapy for COPD are still unclear.

methodsPatients with treatment-naïve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Physical activity was assessed using a triaxle accelerometer for 2 weeks before and after treatment. This analysis focused on the change in sedentary time, indicated by physical activity of 1.0-1.5 metabolic equivalents (METs), with stratification for the following factors: age, body mass index (BMI), pulmonary function, COPD assessment test (CAT), the 6-minute walk distance (6MWD), and physical activity level at study entry.

resultsThirty-five patients received tiotropium/olodaterol and 34 patients received tiotropium. In patients with lower inspiratory capacity at study entry, a significant reduction in sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -12.8 ± 13.5 min, Tio/Olo: -65.1 ± 21.0 min, mean difference, -52.2 min, 95% CI -103.6 to 0.88, p = 0.046). In patients with a shorter duration of physical activity of ≥2 METs at study entry, a significant reduction of sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -3.3 ± 17.5 min, Tio/Olo: -72.9 ± 23.1 min, mean difference, -69.7 min, 95% CI -128.7 to -10.6, p = 0.02). There were no differences in terms of age, BMI, CAT score, 6MWD, FEV1, FVC, VC, and physical activity of 1.0-1.5 METs and ≥3.0 METs.

conclusionThis study showed that COPD patients with lower inspiratory capacity or shorter active time of ≥2.0 METs at study entry are likely to exhibit significantly greater reduction in sedentary time with tiotropium/olodaterol treatment.

Indexed as

Pulmonary Disease, Chronic ObstructiveSedentary BehaviorAdministration, InhalationAdrenergic beta-2 Receptor AgonistsBenzoxazinesBronchodilator AgentsDrug CombinationsForced Expiratory VolumeHumansTiotropium BromideTreatment OutcomeAdrenergic beta-2 Receptor AgonistsBenzoxazinesBronchodilator AgentsDrug CombinationsolodaterolTiotropium Bromidechronic obstructive pulmonary diseaselong-acting beta 2 agonistlong-acting muscarinic antagonistphysical activitysedentary time

Identifiers

PMID34908832
PMCPMC8664652
OpenAlexW4200495172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.